WRAPSODY 动静脉通路疗效试验随机对照臂的 6 个月安全性与有效性结果
这项前瞻性国际多中心关键试验(NCT04540302)纳入 245 例静脉流出道狭窄的血液透析患者,随机接受新型细胞不可渗透腔内移植物(CIE,122 例)或经皮腔内血管成形术(PTA,123 例)。6 个月靶病变原发通畅率(TLPP)和通路回路原发通畅率(ACPP)CIE 组均显著高于 PTA 组,30 天安全性事件免于发生率两组无统计学差异。
要点
- 6 个月 TLPP:CIE 89.6% vs PTA 62.3%;ACPP:72.2% vs 57.0%。
- 30 天安全性事件免于发生率 CIE 96.6% vs PTA 95.0%,无统计学差异。
- 两组不良事件未见差异。
核心结论
- 在 AVF 狭窄患者中,CIE 在 6 个月 TLPP 和 ACPP 方面优于 PTA,30 天主要安全性事件无差异。
研究设计与样本
- 前瞻性、国际、多中心关键试验(NCT04540302),245 例静脉流出道狭窄患者随机分为 CIE 组 122 例和 PTA 组 123 例,覆盖 43 个国际中心。
主要发现
- 6 个月 TLPP 在 CIE 组为 89.6%,PTA 组为 62.3%。
- 6 个月 ACPP 在 CIE 组为 72.2%,PTA 组为 57.0%。
- 30 天安全性事件免于发生率 CIE 组 96.6%,PTA 组 95.0%,无统计学显著差异。
- 两组不良事件无差异。
关键数值与推荐
- 主要终点包括 6 个月靶病变原发通畅率(免于临床驱动的靶病变血运重建或靶病变血栓形成)和索引术后 30 天内影响通路回路并导致再干预、住院或死亡的安全性事件免于发生率。
- 通路回路原发通畅率作为次要疗效终点评估。
临床怎么用
- 对于 AVF 静脉流出道狭窄的血液透析患者,CIE 可作为 PTA 之外的选项,以改善 6 个月靶病变和通路回路原发通畅率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stenosis within the arteriovenous fistula (AVF) of hemodialysis patients leads to vascular access dysfunction and inadequate hemodialysis. Percutaneous transluminal angioplasty (PTA) is the standard therapy for stenosis. However, rates of restenosis and loss of access patency remain high. Outcomes of a novel cell-impermeable endoprosthesis (CIE) have not been investigated in this setting. Therefore, our study was designed to address this as a prospective, international, multicenter pivotal trial (NCT04540302) with 245 patients with stenosis in their venous outflow circuit randomized to treatment: 122 receiving CIE and 123 receiving PTA across 43 international centers. Primary endpoints included target lesion primary patency (TLPP) at six months (freedom from clinically driven target lesion revascularization or target lesion thrombosis) and freedom from safety events through 30 days post-index procedure that affected the access circuit and resulted in reintervention, hospitalization, or death. Access circuit primary patency (ACPP) was evaluated as a secondary efficacy endpoint. Six-month TLPP and ACPP were significantly higher for the CIE cohort versus PTA (TLPP: 89.6% vs. 62.3%; ACPP: 72.2% vs. 57.0%). Thirty days post-index procedure, there was no statistically significant difference in the freedom from safety events for the CIE versus PTA (96.6 vs. 95.0%). No differences were observed in adverse events between either cohort. Our study shows that among patients with stenosis in their AVF, the CIE was superior to PTA with respect to six-month TLPP and ACPP with no observed difference in 30-day primary safety events.
引用
- Razavi MK, Balamuthusamy S, Makris AN, et al. Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial. Kidney Int. 2025. PMID: 39862972. doi:10.1016/j.kint.2025.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。